All Posts Tagged With: "ABII"
(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58.
Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development...
(CELG) Celgene Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58.
Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(GIS) Company News for June 30, 2010 – Corporate Summary
• General Mills (NYSE:GIS) raised its dividend before reporting inline fiscal fourth-quarter earnings of 41 cents a share, but its guidance for fiscal 2011 came in below Street expectations. Revenues of $3.57 billion were in-line with Zacks projections of $3.57 billion,...
(MEDX) Top Delaware Funds – Mutual Fund Education
Delaware Trend A (DELTX) seeks long-term capital appreciation by primarily investing in small, growth-oriented or emerging companies.
The fund uses a bottom-up approach to create a portfolio and normally maintains its position in a stock...